Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

TNXP vs TLPH: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TLPH Captures Overall Composite Edge (37.1 SELL vs 42.6 HOLD), While TNXP Leads 3–2 on Growth & Valuation Pillars

TLPH Overall Winner 6-Pillar Tally: TNXP 3 – 2 TLPH (1 Tie) Matrix Metrics: TNXP 4 – 4 TLPH

As of Nov 16, 2026, Talphera, Inc. (TLPH) captures the overall head-to-head institutional edge over Tonix Pharmaceuticals Holding Corp. (TNXP) on higher Unified Composite conviction (37.1/100 SELL vs. 42.6/100 HOLD) after splitting the core matrix 4–4 (led by Valuation Multiples, Options & Positioning), while TNXP wins 3–2 across the 6-pillar growth and valuation breakdown. TNXP trades at $2.87 (N/M Forward P/E, -436.2% operating margin) versus TLPH at $0.86 (1.0x Forward P/E, -1474700.0% operating margin).

  • Composite vs. Pillar Nuance: While TNXP currently prints a higher short-term Unified Composite Score (42.6/100 HOLD vs. TLPH 37.1/100 SELL), TLPH captures the overall institutional head-to-head verdict (4–4 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (-1474700.0% vs. -436.2% operating margin) and revenue trajectory (+0.0% vs. +423.8% YoY).
  • Technical & Structure Timing Caution: TNXP is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 10.6); meanwhile TLPH is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About TNXP vs TLPH
TNXP NASDAQ
Tonix Pharmaceuticals Holding Corp.
Pharmaceutical Preparations
$2.87
-4.7% 1D
Market Cap $63.0M
TTM Revenue $43M
Forward P/E N/M
Beta / 30D Vol 1.73β · 76% Vol
Unified Composite Score
42.6 / 100 HOLD
Tech 25.0 Fund 44.0 Flow 66.0 Mom 44.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -30.6%), weak momentum, RSI 11
RSI-14: 10.6 · SMA20: $4.71 · SMA50: $7.51
TLPH NASDAQ Head-to-Head Winner
Talphera, Inc. Common Stock
Pharmaceutical Preparations
$0.86
-4.98% 1D
Market Cap $53.7M
TTM Revenue $1,000
Forward P/E 1.0x
Beta / 30D Vol 1.11β · 58% Vol
Unified Composite Score
37.1 / 100 SELL
Tech 25.0 Fund 45.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.8%), weak momentum, RSI 26
RSI-14: 26.1 · SMA20: $1.04 · SMA50: $1.10

6-Pillar Scorecard Institutional Category Breakdown (TNXP 3 – 2 TLPH)

Columns: Metric · TNXP · TLPH
1. Valuation Multiples TLPH
Forward P/E N/M 1.0x
Trailing P/E N/M 1.0x
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale TNXP
Revenue Growth (YoY) +423.8% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $43M $1,000
Market Cap $63.0M $53.7M
3. Profitability & Quality TNXP
Gross Margin 89.3% N/A
Operating Margin -436.2% -1474700.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -84.1% -143.4%
4. Balance Sheet & Cash Flow TNXP
Cash Generation (TTM) -$185M EBITDA -$15M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $162M Net Cash $0.28 Book/Sh · -143.4% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning TLPH
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 82.4% (21st %ile) 118.4% (100th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: TNXP (4) vs TLPH (4)
Institutional Metric TNXP TLPH Criterion Row Edge
Market Capitalization
Scale
$63.0M $53.7M Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M 1.0x Lower Multiple TLPH
Forward P/E Ratio
Valuation
N/M 1.0x Lower Multiple TLPH
Revenue Growth (YoY)
Growth
+423.8% +0.0% Higher Growth TNXP
Operating Margin (TTM)
Profitability
-436.2% -1474700.0% Higher Margin TNXP
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-84.1% -143.4% Higher ROE TNXP
52-Week Range Position
Momentum
0% ($3–$21) 20% ($1–$2) Stronger Trend TLPH
Beta / 30D Volatility
Risk Regime
1.73β · 76% Vol 1.11β · 58% Vol Lower Realized Risk TLPH
Unified Institutional Score
Composite Signal
42.6 / 100 (HOLD) 37.1 / 100 (SELL) Higher Composite TNXP
Trailing 12M Revenue (USD)
Operating Scale
$43M $1,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
89.3% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$185M EBITDA ($162M Net Cash) -$15M EBITDA ($0.28 Book/Sh · -143.4% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon TLPH +32.22 pp
TNXP: -52.51% · TLPH: -20.29%
3M Horizon TLPH +48.49 pp
TNXP: -77.34% · TLPH: -28.85%
6M Horizon TLPH +87.86 pp
TNXP: -79.88% · TLPH: +7.98%
1Y Horizon TLPH +64.23 pp
TNXP: -82.24% · TLPH: -18.01%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TNXP vs TLPH. Trailing 12-month operating profitability (TNXP -436.2% vs TLPH -1474700.0%) and valuation multiples (TNXP N/M vs TLPH 1.0x Forward P/E) are benchmarked directly in Pillar 4 below.

TNXP ADR TTM Benchmark FX-Normalized USD
TTM Revenue$43M
Gross Margin89.3%
Op. Margin-436.2%
ROE / Fwd P/E-84.1% · N/M
TLPH ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1,000
Gross MarginN/A
Op. Margin-1474700.0%
ROE / Fwd P/E-143.4% · 1.0x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
TNXP BREAKDOWN
54d in phase · OBV DISTRIBUTION
Current IV 82.4%
IV Percentile 21st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact TNXP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
TLPH UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 118.4%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TLPH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
TNXP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $63.0M market capitalization and -436.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
TLPH Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $53.7M market capitalization and -1474700.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ TNXP vs TLPH Key Questions & Quantitative Answers

As of Nov 16, 2026, Talphera, Inc. (TLPH) captures the overall head-to-head institutional edge over Tonix Pharmaceuticals Holding Corp. (TNXP) on higher Unified Composite conviction (37.1/100 SELL vs. 42.6/100 HOLD) after splitting the core matrix 4–4 (led by Valuation Multiples, Options & Positioning), while TNXP wins 3–2 across the 6-pillar growth and valuation breakdown. TNXP trades at $2.87 (N/M Forward P/E, -436.2% operating margin) versus TLPH at $0.86 (1.0x Forward P/E, -1474700.0% operating margin). Composite vs. Pillar Nuance: While TNXP currently prints a higher short-term Unified Composite Score (42.6/100 HOLD vs. TLPH 37.1/100 SELL), TLPH captures the overall institutional head-to-head verdict (4–4 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (-1474700.0% vs. -436.2% operating margin) and revenue trajectory (+0.0% vs. +423.8% YoY). Technical & Structure Timing Caution: TNXP is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 10.6); meanwhile TLPH is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

TNXP leads the Growth & Scale pillar: TNXP posts +423.8% YoY revenue growth and +0.0% YoY earnings growth on $43M TTM revenue (89.3% gross margin, -436.2% operating margin), compared with TLPH at +0.0% YoY revenue growth and +0.0% YoY earnings growth on $1,000 TTM revenue (N/A gross margin, -1474700.0% operating margin). On trailing 12-month operating scale, TNXP generates $43M in USD-normalized revenue versus $1,000 for TLPH. In operating R&D and SG&A reinvestment, TNXP deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for TLPH.

TLPH screens cheaper on headline valuation multiples. TNXP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin), whereas TLPH trades at 1.0x Forward P/E, 1.0x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TNXP (-84.1% ROE) versus TLPH (-143.4% ROE) capital efficiency.

In options market volatility and institutional positioning, TNXP carries 82.4% implied volatility (21st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.73β · 76% Vol realized risk). By comparison, TLPH carries 118.4% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.11β · 58% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.